When Giants Stumble: UnitedHealth Group, A Buy Opportunity?
$UnitedHealth(UNH)$ stands as a leading global healthcare management company, providing services to individuals in the United States and numerous other countries. The firm is notable for its extensive diversification as a payer, evident across its varied product offerings, wide geographical footprint, and broad range of customer segments. UNH's core operations are structured into several key divisions: UnitedHealthcare, OptumRx, OptumInsight, and OptumHealth.
Inside UNH's Scramble to Reverse Profit Plunge Amidst Leadership Upheaval
UnitedHealth Group is currently navigating a complex gauntlet of leadership changes, severe operational disruptions, and starkly declining profitability—a situation now drawing intense investor scrutiny. The healthcare behemoth, despite its formidable scale and a history of impressive top-line expansion, saw its 2024 financial performance significantly marred. This has raised pressing questions about its near-term trajectory and its fundamental ability to convert burgeoning revenue into sustainable profit growth.
The turmoil ignited with the May 13, 2025, announcement: Andrew Witty stepped down as CEO, precipitating the immediate return of former chief executive (2006-2017) Stephen Hemsley. This abrupt leadership shuffle coincided with UNH's decision to suspend its 2025 financial outlook. Adding to the prevailing uncertainty, the company has deferred its updated 2025 guidance, initially anticipated around July 15th, until its second-quarter results presentation on July 29th.
The financial narrative for 2024 was challenging, standing in contrast to a decade of robust growth. While total revenues climbed to an impressive $400.3 billion (up from $371.6 billion in 2023 and a substantial leap from $157.1 billion in 2015), this expansion failed to reach the bottom line. Net Income plummeted to $14.4 billion, or $15.51 per share, a steep fall from the prior year's $22.4 billion, or $23.86 per share.
This precipitous decline was notably influenced by factors such as the Change Healthcare cyberattack, which alone inflicted costs around $3.1 billion. Consequently, Return on Revenue for 2024 cratered to 3.60% from 6.02% in 2023, and Return on Equity contracted sharply to 15.10% from a strong 25.00% (and historical levels typically ranging between 23-25%). This 2024 downturn amplified an already concerning longer-term trend: a five-year (2019-2024) revenue Compound Annual Growth Rate of Revenue (CAGR) of approximately 11% yielded a meager ~2% EPS CAGR. However, it's important to recognize a counterpoint: Operating Earnings per share, a key indicator of core business strength, have consistently climbed over the decade—from $11.40 in 2015 to $34.75 in 2024. This underlying resilience suggests the recent sharp decline in net income might stem more from specific, albeit significant, charges and acute margin pressures than from a fundamental decay in UNH's operational earning power.
Both of UNH’s major segments felt the strain in 2024. UnitedHealthcare continues to grapple with escalating medical cost trends, particularly within its critical Medicare Advantage business. Meanwhile, Optum, the company's services arm and historically a potent growth engine, saw its 2024 operating margin dip to 6.6% (or 7.2% excluding Change Healthcare impacts), down from 7.0% in 2023.
Under Hemsley's renewed leadership, the immediate agenda will focus on stabilizing operations, overhauling medical trend forecasting, and restoring battered margin credibility. Debt has steadily climbed from $33.8 billion in 2015 to $92.7 billion by year-end 2024, a figure that now alarmingly matches its common equity of $92.7 billion. This underscores an urgent need for meticulous capital management amidst deeply pressured earnings.
The Bottom Line: UnitedHealth Group, a titan of the healthcare industry, is clearly navigating a perfect storm of internal and external pressures. Its formidable scale, diversified operations, and the strategic importance of Optum remain significant long-term assets. However, the substantial earnings reset in 2024, coupled with persistent uncertainties around medical costs and the efficacy of its new (yet familiar) leadership to execute a convincing turnaround, warrants a cautious stance. The July 29th update is thus shaping up to be a critical inflection point for UNH 0.18%↑ .
Technical Analysis:
The price is finding support at a confluent level, including the point of control of the current volume shelf (black arrow) and the top before the COVID crash. On the other hand, the RSI is the most oversold it has been since the Great Financial Crisis, not even reaching such levels during the COVID downturn.
The price is brewing a bounce, even if it's just a dead cat bounce. Mark your calendar for July 29th, when news may be priced in following a very likely recovery. In June, the odds for a bounce to $336 are very high (a 10% bounce). Once that level is reached, the daily and weekly price action (candlesticks and oscillators) must be assessed before considering continuation or rejection.
For this week, a bounce remains in play as long as the price stays above $298.9, with an immediate target at $308.7 (which already acted as resistance today). If $298.9 is breached, $292.1 is the support level that may hold the price and where the bounce thesis for June is put in hold.
Considering the long-term support levels mentioned above, technical analysis suggests risk favors bulls, given the oversold conditions and strong fundamentals already discussed.
For whom haven't open CBA can know more from below:
🏦 Open a CBA today and enjoy privileges of up to SGD 20,000 in trading limit with 0 commission. Trade SG, HK, US stocks as well as ETFs unlimitedly!
Find out more here：
Trade on a Cash Boost Account and enjoy up to 6 months of Commission-Free trading.
💰Join the TB Contra Telegram Group to Get $10 Trading Vouchers Now🎉
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
